Angle PLC Announces Parsortix enriched CTC & ctDNA in NSCLC patients
ANGLE plc announced research findings on dual analysis of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in non-small cell lung cancer (NSCLC) patients. The study, conducted by the National and Kapodistrian University of Athens, used the Parsortix system to analyze 30 NSCLC patients treated with osimertinib. The research demonstrated that dual analysis of CTC-DNA and ctDNA provides complementary information, enabling better identification of resistance mutations and DNA methylation at disease progression. The study also revealed druggable molecular markers that could inform combined targeted treatment approaches, supporting ANGLE's pharma services strategy.
ANGLE plc ha annunciato i risultati di una ricerca sulla doppia analisi delle cellule tumorali circolanti (CTC) e del DNA tumorale circolante (ctDNA) nei pazienti affetti da cancro ai polmoni non a piccole cellule (NSCLC). Lo studio, condotto dall'Università Nazionale e Kapodistriana di Atene, ha utilizzato il Parsortix system per analizzare 30 pazienti NSCLC trattati con osimertinib. La ricerca ha dimostrato che la doppia analisi di CTC-DNA e ctDNA fornisce informazioni complementari, consentendo una migliore identificazione delle mutazioni di resistenza e della metilazione del DNA durante la progressione della malattia. Lo studio ha anche rivelato marcatori molecolari utilizzabili per farmaci che potrebbero informare approcci di trattamento mirati combinati, supportando la strategia dei servizi farmaceutici di ANGLE.
ANGLE plc anunció los resultados de una investigación sobre el análisis dual de células tumorales circulantes (CTC) y ADN tumoral circulante (ctDNA) en pacientes con cáncer de pulmón de células no pequeñas (NSCLC). El estudio, llevado a cabo por la Universidad Nacional y Kapodistriana de Atenas, utilizó el Parsortix system para analizar a 30 pacientes con NSCLC tratados con osimertinib. La investigación demostró que el análisis dual de CTC-DNA y ctDNA proporciona información complementaria, lo que permite una mejor identificación de las mutaciones de resistencia y la metilación del ADN en la progresión de la enfermedad. El estudio también reveló marcadores moleculares que podrían informar sobre enfoques de tratamiento dirigido combinados, apoyando la estrategia de servicios farmacéuticos de ANGLE.
ANGLE plc는 비소세포 폐암(NSCLC) 환자에서 순환 종양 세포(CTC)와 순환 종양 DNA(ctDNA)의 이중 분석에 대한 연구 결과를 발표했습니다. 아테네 국립 카포디스트리안 대학교에서 실시한 이 연구는 Parsortix system을 사용하여 오시머티닙으로 치료받은 30명의 NSCLC 환자를 분석했습니다. 연구 결과, CTC-DNA와 ctDNA의 이중 분석이 보완적인 정보를 제공하여 질병 진행 시 저항 돌연변이 및 DNA 메틸화의 보다 나은 식별을 가능하게 한다는 것이 입증되었습니다. 또한 이 연구는 결합된 표적 치료 접근 방식을 알릴 수 있는 약리 활성 분자 마커를 밝혀내어 ANGLE의 제약 서비스 전략을 지원했습니다.
ANGLE plc a annoncé les résultats d'une recherche sur l'analyse duale des cellules tumorales circulantes (CTC) et de l'ADN tumoral circulant (ctDNA) chez des patients atteints de cancer du poumon non à petites cellules (NSCLC). L'étude, menée par l'Université nationale et kapodistrienne d'Athènes, a utilisé le Parsortix system pour analyser 30 patients NSCLC traités par osimertinib. La recherche a démontré que l'analyse duale du CTC-DNA et du ctDNA fournit des informations complémentaires, permettant une meilleure identification des mutations de résistance et de la méthylation de l'ADN lors de la progression de la maladie. L'étude a également révélé des marqueurs moléculaires exploitables pouvant informer des approches de traitement ciblé combinées, soutenant la stratégie de services pharmaceutiques d'ANGLE.
ANGLE plc gab die Ergebnisse einer Forschung zur dualen Analyse von zirkulierenden Tumorzellen (CTC) und zirkulierendem Tumor-DNA (ctDNA) bei Patienten mit nicht-kleinzelligem Lungenkrebs (NSCLC) bekannt. Die Studie, die von der Nationalen und Kapodistrianischen Universität Athen durchgeführt wurde, verwendete das Parsortix system, um 30 NSCLC-Patienten zu analysieren, die mit Osimertinib behandelt wurden. Die Forschung zeigte, dass die duale Analyse von CTC-DNA und ctDNA ergänzende Informationen liefert, die eine bessere Identifizierung von Resistenzmutationen und DNA-Methylierung bei Krankheitsprogression ermöglichen. Darüber hinaus wurden behandelbare molekulare Marker entdeckt, die kombinierte zielgerichtete Therapieansätze unterstützen könnten und die Pharma-Services-Strategie von ANGLE fördern.
- Dual analysis technique showed improved detection of EGFR T790M resistance mutation
- Identified additional druggable molecular markers (HER2, PD-L1, PIM-1, AXL)
- Technology demonstrates potential for better patient stratification in clinical trials
- Study supports company's pharma services business strategy
- None.
ANGLE plc ("the Company")
DNA ANALYSIS OF PARSORTIX-ENRICHED CTCS AND CTDNA PROVIDES COMPLEMENTARY INFORMATION IN NSCLC PATIENTS TREATED WITH ASTRAZENECA'S OSIMERTINIB
The addition of CTC-DNA analysis to clinical trials could identify patients developing treatment resistance prior to disease progression
CTC analysis identifies druggable targets which could be used to inform combined targeted treatment
GUILDFORD, SURREY / ACCESSWIRE / November 11, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce the publication of research investigating the dual analysis of CTCs and circulating tumour DNA (ctDNA) in non-small cell lung cancer (NSCLC), undertaken by the National and Kapodistrian University of Athens.
Researchers used the Parsortix® system to isolate and harvest CTCs from 30 patients with EGFR-mutated NSCLC that were undergoing treatment with osimertinib (TAGRISSO: AstraZeneca). Osimertinib is an EGFR inhibitor with annual revenues of c. US
The study provides further evidence that complementary information can be obtained through dual analysis of CTC-DNA and ctDNA. Using the dual analysis technique, at disease progression an increased number of patients were identified with the EGFR T790M resistance mutation and DNA methylation, compared to analysis of either analyte alone. Dual analysis of these liquid biopsy analytes enables longitudinal monitoring of patients throughout clinical trials and may enable early identification of non-responders and identify patients becoming resistant to treatment before disease progression.
Additional analysis of CTCs identified druggable molecular markers, such as HER2, PD-L1, PIM-1 and AXL, at study baseline and at disease progression, providing information on the potential benefits of combined targeted treatment, and possible suitable therapies for those patients whose cancer progresses due to resistance to osimertinib. This adds to the body of evidence supporting ANGLE's large pharma strategy, highlighting the potential to aid in the stratification of patients that may benefit from alternative/combinatorial therapies being investigated in clinical trials.
Chief Scientific Officer, Karen Miller, commented:
"This study supports our pharma services business by demonstrating how dual molecular analysis of Parsortix-enriched CTCs and ctDNA could improve patient stratification in clinical trials investigating new targeted therapies or new therapy combinations. This approach could ultimately lead to the development of more targeted drugs or better drug combinations that could result in better outcomes for patients, all of which may require a Parsortix-based companion diagnostic to support regulatory approval."
The research, published as a peer-reviewed publication in the journal Frontiers in Oncology, is available online at https://angleplc.com/resources/publications/.
For further information:
ANGLE plc | +44 (0) 1483 343434 |
Berenberg (NOMAD and Broker) | +44 (0) 20 3207 7800 |
FTI Consulting |
|
For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/
Notes for editors
About ANGLE plc
ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected CTC harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.
ANGLE's commercial businesses are focusing on clinical services and diagnostic products. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma. Products include the Parsortix system, associated consumables and assays.
Over 100 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit www.angleplc.com
Any reference to regulatory authorisations such as FDA clearance, CE marking or UK MHRA registration shall be read in conjunction with the full intended use of the product:
The Parsortix® PC1 system is an in vitro diagnostic device intended to enrich circulating tumor cells (CTCs) from peripheral blood collected in K2EDTA tubes from patients diagnosed with metastatic breast cancer. The system employs a microfluidic chamber (a Parsortix cell separation cassette) to capture cells of a certain size and deformability from the population of cells present in blood. The cells retained in the cassette are harvested by the Parsortix PC1 system for use in subsequent downstream assays. The end user is responsible for the validation of any downstream assay. The standalone device, as indicated, does not identify, enumerate or characterize CTCs and cannot be used to make any diagnostic/prognostic claims for CTCs, including monitoring indications or as an aid in any disease management and/or treatment decisions.
All results reported in this announcement and any other products and services are for research use only and not for use in diagnostic procedures.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: ANGLE plc
View the original press release on accesswire.com
FAQ
What did ANGLE plc's (ANPCY) latest study on NSCLC patients reveal?
How many NSCLC patients were included in ANGLE plc's (ANPCY) Parsortix system study?
What molecular markers did ANGLE plc's (ANPCY) CTC analysis identify in NSCLC patients?
